机构：[1]Department of Biomedical Sciences, City University of Hong Kong,Hong Kong, China[2]Key Laboratory of Biochip Technology, Biotechand Health Centre, Shenzhen Research Institute of City University ofHong Kong, Shenzhen, China[3]Division of Life Science, Hong KongUniversity of Science and Technology, Hong Kong, China[4]State KeyLaboratory of Protein and Plant Gene Research, School of LifeSciences and Peking-Tsinghua Center for Life Sciences, PekingUniversity, Peking, China[5]School of Biomedical Sciences, TheUniversity of Hong Kong, Hong Kong, China[6]Ming Wai Lau Centrefor Reparative Medicine, Karolinska Institutet, Hong Kong, China[7]State Key Laboratory of Biotherapy and Cancer Center, West ChinaHospital, West China Medical School, Sichuan University, Sichuan,China四川大学华西医院[8]Department of Molecular Diagnostics and ExperimentalTherapeutics, Beckman Research Institute at City of HopeComprehensive Cancer Center, Duarte, CA, USA
Research Grants Council Hong Kong [Project Nos. 17101814,
21100615, 11102118, 11101919 (to K.M.C.), 11102317 (to X.W.), 26100214 (to T.I.) and
C7007-17GF (to M.S.Y.H., K.M.C., and T.I.)], the Shenzhen Science and Technology
Fund Program Project Nos. JCYJ20170818104203065, JCYJ20180307124019360 (to K.
M.C.) and JCYJ20170307091256048 (to X.W.), and National Natural Science
Foundation of China [Project No. 81802384 (to X.W.)]. This work was also supported
by the Hong Kong Epigenomics Project of the EpiHK (to K.M.C.) and grants from the
National Cancer Institute, National Institute of Health [CA72851, CA187956,
CA202797, and CA214254 (to A.G.)].
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2020]版：
大类|1 区医学
小类|1 区生化与分子生物学1 区细胞生物学
最新[2023]版：
大类|1 区医学
小类|1 区生化与分子生物学1 区细胞生物学
第一作者：
第一作者机构：[1]Department of Biomedical Sciences, City University of Hong Kong,Hong Kong, China[2]Key Laboratory of Biochip Technology, Biotechand Health Centre, Shenzhen Research Institute of City University ofHong Kong, Shenzhen, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Biomedical Sciences, City University of Hong Kong,Hong Kong, China[2]Key Laboratory of Biochip Technology, Biotechand Health Centre, Shenzhen Research Institute of City University ofHong Kong, Shenzhen, China
推荐引用方式(GB/T 7714)：
Yi Ching Esther Wan,Tsz Chui Sophia Leung,Dongbo Ding,et al.Cancer-associated histone mutation H2BG53D disrupts DNA-histone octamer interaction and promotes oncogenic phenotypes.[J].Signal transduction and targeted therapy.2020,5(1):27.doi:10.1038/s41392-020-0131-0.
APA：
Yi Ching Esther Wan,Tsz Chui Sophia Leung,Dongbo Ding,Xulun Sun,Jiaxian Liu...&Kui Ming Chan.(2020).Cancer-associated histone mutation H2BG53D disrupts DNA-histone octamer interaction and promotes oncogenic phenotypes..Signal transduction and targeted therapy,5,(1)
MLA：
Yi Ching Esther Wan,et al."Cancer-associated histone mutation H2BG53D disrupts DNA-histone octamer interaction and promotes oncogenic phenotypes.".Signal transduction and targeted therapy 5..1(2020):27
医学